74 related articles for article (PubMed ID: 30405212)
41. High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors.
Bonjoch A; Juega J; Puig J; Pérez-Alvarez N; Aiestarán A; Echeverría P; Pérez V; Clotet B; Romero R; Bonet J; Negredo E
AIDS Patient Care STDS; 2014 Oct; 28(10):524-9. PubMed ID: 25238104
[TBL] [Abstract][Full Text] [Related]
42. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.
Hemkens LG; Ewald H; Santini-Oliveira M; Bühler JE; Vuichard D; Schandelmaier S; Stöckle M; Briel M; Bucher HC
HIV Clin Trials; 2015 Oct; 16(5):178-89. PubMed ID: 26395328
[TBL] [Abstract][Full Text] [Related]
43. The Epi-TAF for Tenofovir Disoproxil Fumarate?
Walensky RP; Horn TH; Paltiel AD
Clin Infect Dis; 2016 Apr; 62(7):915-8. PubMed ID: 26658300
[TBL] [Abstract][Full Text] [Related]
44. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
Bedimo R; Rosenblatt L; Myers J
HIV Clin Trials; 2016 Nov; 17(6):246-266. PubMed ID: 27809711
[TBL] [Abstract][Full Text] [Related]
45. Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy Is Not Associated With Adverse Perinatal Outcomes Among HIV-infected East African Women: A Prospective Study.
Pintye J; Baeten JM; Celum C; Mugo N; Ngure K; Were E; Bukusi EA; John-Stewart G; Heffron RA
J Infect Dis; 2017 Dec; 216(12):1561-1568. PubMed ID: 29040666
[TBL] [Abstract][Full Text] [Related]
46. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
[TBL] [Abstract][Full Text] [Related]
47. Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veterans.
Kim JE; Scherzer R; Estrella MM; Ix JH; Shlipak MG
AIDS; 2016 Apr; 30(7):1049-57. PubMed ID: 26760455
[TBL] [Abstract][Full Text] [Related]
48. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
[TBL] [Abstract][Full Text] [Related]
49. Association of tenofovir disoproxil fumarate with primary allograft survival in HIV-positive kidney transplant recipients.
Boyle SM; Malat G; Harhay MN; Lee DH; Pang L; Talluri S; Sharma A; Bias TE; Ranganna K; Doyle AM
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28520146
[TBL] [Abstract][Full Text] [Related]
50. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
[TBL] [Abstract][Full Text] [Related]
51. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
52. Association between tenofovir plasma trough concentrations in the early stage of administration and discontinuation of up to five years tenofovir disoproxil fumarate due to renal function-related adverse events in Japanese HIV-1 infected patients.
Yagura H; Watanabe D; Nakauchi T; Kushida H; Hirota K; Nishida Y; Yoshino M; Uehira T; Shirasaka T
J Pharm Health Care Sci; 2024 May; 10(1):20. PubMed ID: 38730311
[TBL] [Abstract][Full Text] [Related]
53. Tenofovir disoproxil fumarate-induced distal renal tubular acidosis: A case report.
Salimi R; Begum I; Varma DM; Nandakrishna B; Rajesh R; Vidyasagar S
Int J STD AIDS; 2020 Mar; 31(3):276-279. PubMed ID: 31996094
[No Abstract] [Full Text] [Related]
54. Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials.
Ngongondo M; Ritz J; Hughes MD; Matoga M; Hosseinipour MC;
PLOS Glob Public Health; 2024; 4(1):e0002648. PubMed ID: 38175824
[TBL] [Abstract][Full Text] [Related]
55. Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate.
Phuphuakrat A; Pasomsub E; Chantratita W; Mahasirimongkol S; Disthabanchong S; Sungkanuparph S; Kiertiburanakul S
J Int Assoc Provid AIDS Care; 2022; 21():23259582221134751. PubMed ID: 36314476
[TBL] [Abstract][Full Text] [Related]
56. Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B.
Boglione L; De Benedetto I; Dodaro V; Chiecchio M; De Nicolò A; Di Perri G; D'Avolio A
Arch Virol; 2022 Aug; 167(8):1669-1674. PubMed ID: 35598207
[TBL] [Abstract][Full Text] [Related]
57. ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment.
Cheli S; Baldelli S; De Silvestri A; Fusi M; Minisci D; Gervasoni C; Cattaneo D; Clementi E; Meraviglia P; Montrasio C
Pharmacogenomics J; 2021 Oct; 21(5):586-593. PubMed ID: 33850298
[TBL] [Abstract][Full Text] [Related]
58. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?
Calcagno A; Fiumanò M; Zugna D; Cusato J; Montrucchio C; Marinaro L; Trentini L; Ferrara M; D'Avolio A; Pizzi C; Di Perri G; Bonora S
Pharmacogenomics J; 2019 Feb; 19(1):65-71. PubMed ID: 30405212
[TBL] [Abstract][Full Text] [Related]
59. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
[TBL] [Abstract][Full Text] [Related]
60. Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana.
Chadwick DR; Sarfo FS; Kirk ES; Owusu D; Bedu-Addo G; Parris V; Owusu AL; Phillips R
BMC Nephrol; 2015 Dec; 16():195. PubMed ID: 26627687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
